-
1
-
-
34147164484
-
Neuroprotection in Parkinson's disease: an elusive goal
-
Biglan KM, Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Semin Neurol 2007; 27: 106-112.
-
(2007)
Semin Neurol
, vol.27
, pp. 106-112
-
-
Biglan, K.M.1
Ravina, B.2
-
2
-
-
0025651148
-
Striatonigral degeneration. A clinicopathological study
-
Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990; 113: 1823-1842.
-
(1990)
Brain
, vol.113
, pp. 1823-1842
-
-
Fearnley, J.M.1
Lees, A.J.2
-
3
-
-
2942647959
-
Central nervous system atrophy and clinical status in multiple sclerosis
-
Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004; 14: 27S-35S.
-
(2004)
J Neuroimaging
, vol.14
-
-
Zivadinov, R.1
Bakshi, R.2
-
4
-
-
70349456475
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease
-
Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
-
(2009)
N Engl J Med
, vol.361
, pp. 1268-1278
-
-
Olanow, C.W.1
Rascol, O.2
Hauser, R.3
-
5
-
-
0024343466
-
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
-
Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-522.
-
(1989)
Science
, vol.245
, pp. 519-522
-
-
Tetrud, J.W.1
Langston, J.W.2
-
6
-
-
0029790469
-
Observations and suggestions on antidementia drug development
-
Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996; 10: 31-35.
-
(1996)
Alzheimer Dis Assoc Disord
, vol.10
, pp. 31-35
-
-
Leber, P.1
-
7
-
-
0030865454
-
Slowing the progression of Alzheimer disease: methodologic issues
-
Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 1997; 11: 10-21.
-
(1997)
Alzheimer Dis Assoc Disord
, vol.11
, pp. 10-21
-
-
Leber, P.1
-
8
-
-
61449173973
-
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics
-
Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008; 23: 2194-2201.
-
(2008)
Mov Disord
, vol.23
, pp. 2194-2201
-
-
Olanow, C.W.1
Hauser, R.A.2
Jankovic, J.3
-
9
-
-
73349136256
-
Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease
-
Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JVS. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009; 11: 456-464.
-
(2009)
AAPS J
, vol.11
, pp. 456-464
-
-
Bhattaram, V.A.1
Siddiqui, O.2
Kapcala, L.P.3
Gobburu, J.V.S.4
-
10
-
-
0347093537
-
The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint
-
Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 2004; 23: 305-314.
-
(2004)
Stat Med
, vol.23
, pp. 305-314
-
-
Mani, R.B.1
-
11
-
-
70349467696
-
The delayed-start study design
-
D'Agostino RBSr. The delayed-start study design. N Engl J Med 2009; 361: 1304-1306.
-
(2009)
N Engl J Med
, vol.361
, pp. 1304-1306
-
-
D'Agostino Sr, R.B.1
-
12
-
-
40449088027
-
Biomarkers for the early detection of Parkinson's and Alzheimer's disease
-
Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis 2008; 5: 133-136.
-
(2008)
Neurodegener Dis
, vol.5
, pp. 133-136
-
-
Berg, D.1
-
13
-
-
61949280270
-
"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design
-
Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009; 72: S51-S58.
-
(2009)
Neurology
, vol.72
-
-
Rascol, O.1
-
15
-
-
84859846991
-
Defining at-risk populations for Parkinson's disease: lessons from ongoing studies
-
Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012; 27: 656-665.
-
(2012)
Mov Disord
, vol.27
, pp. 656-665
-
-
Berg, D.1
Marek, K.2
Ross, G.W.3
Poewe, W.4
-
16
-
-
77956808929
-
Defining disease-modifying therapies for PD-a road map for moving forward
-
Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010; 25: 1774-1779.
-
(2010)
Mov Disord
, vol.25
, pp. 1774-1779
-
-
Olanow, C.W.1
Kieburtz, K.2
-
17
-
-
84859874695
-
Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's Disease
-
Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's Disease. Mov Disord 2012; 27: 617-626.
-
(2012)
Mov Disord
, vol.27
, pp. 617-626
-
-
Postuma, R.B.1
Aarsland, D.2
Barone, P.3
-
18
-
-
84863115941
-
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
-
Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198-207.
-
(2012)
Arch Neurol
, vol.69
, pp. 198-207
-
-
Ostrowitzki, S.1
Deptula, D.2
Thurfjell, L.3
-
19
-
-
77949300796
-
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
-
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372.
-
(2010)
Lancet Neurol
, vol.9
, pp. 363-372
-
-
Rinne, J.O.1
Brooks, D.J.2
Rossor, M.N.3
-
20
-
-
84859813166
-
Pre-motor Parkinson's disease: concepts and definitions
-
Siderowf A, Lang AE. Pre-motor Parkinson's disease: concepts and definitions. Mov Disord 2012; 27: 608-616.
-
(2012)
Mov Disord
, vol.27
, pp. 608-616
-
-
Siderowf, A.1
Lang, A.E.2
-
21
-
-
84859856337
-
Motor signs in the prodromal phase of Parkinson's disease
-
Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson's disease. Mov Disord 2012; 27: 627-633.
-
(2012)
Mov Disord
, vol.27
, pp. 627-633
-
-
Maetzler, W.1
Hausdorff, J.M.2
-
22
-
-
84859877206
-
Neuroimaging: current role in detecting pre-motor Parkinson's disease
-
Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K. Neuroimaging: current role in detecting pre-motor Parkinson's disease. Mov Disord 2012; 27: 634-643.
-
(2012)
Mov Disord
, vol.27
, pp. 634-643
-
-
Godau, J.1
Hussl, A.2
Lolekha, P.3
Stoessl, A.J.4
Seppi, K.5
|